Medicine
Yusimry 40 mg/0.8 mL injection
Yusimry 40 mg/0.8 mL injection is a prescription medicine containing Adalimumab for subcutaneous use, marketed by Coherus BioSciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
YUSIMRY must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE…
Key facts
- Active ingredient (INN)
- Adalimumab
- Brand
- Yusimry
- Strength
- 40 mg/0.8 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 2 syringes of 0.8 mL and 1 more
- Marketing authorisation holder
- Coherus BioSciences
- Manufacturers
- Coherus BioSciencesMeitheal Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- YUSIMRY must be refrigerated at 36°F to 46°F (2°C to 8°C). DO NOT FREEZE. Record the date when YUSIMRY is first removed from the refrigerator in the spaces provided on the carton and dose pack. If needed, for example when traveling, YUSIMRY may be stored at room temperature up to a maximum of 77°F (25°C) for a period of up to 14 days, with protection from light.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AB04 Adalimumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 July 2023
- Identifiers
- RxCUI 2640389, 2640395, 2640397 +5DailyMed set ID cd0e7af2-7704-49ce-bde9-f645294b6788, 4cab600d-6950-409f-a6d8-d447da22cd95NDC 70114-210, 70114-220, 71288-815 +1Application BLA761216
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 syringe, glass in 1 carton / .8 mL in 1 syringe, glass | 70114-210-02 | Coherus BioSciences | 1 July 2023 |
| 2 syringe, glass in 1 carton / .8 mL in 1 syringe, glass | 70114-220-02 | Coherus BioSciences | 1 July 2023 |
| 2 syringe, glass in 1 carton / .8 mL in 1 syringe, glass | 71288-815-81 | Meitheal Pharmaceuticals | 1 July 2023 |
| 2 syringe, glass in 1 carton / .8 mL in 1 syringe, glass | 71288-816-81 | Meitheal Pharmaceuticals | 1 July 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Adalimumab 40 mg/0.8 mL injection.
- Amjevita 40 mg/0.8 mL injectionAvailable on requestAmgenUS FDA7 packs Cold chain
- Hadlima 40 mg/0.8 mL injectionAvailable on requestOrganonUS FDA5 packs
- Hyrimoz 40 mg/0.8 mL injectionAvailable on requestCordavisUS FDA2 packs Cold chain
- Hadlima 40 mg/0.8 mL injectionAvailable on requestA-S Medication SolutionsUS FDA1 pack
Other strengths and forms of Adalimumab
Clinical summary
Adalimumab is a tumor necrosis factor blocker indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. MedsAcross supplies Adalimumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AdalimumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Humira prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
- Humira: European public assessment report (EPAR) · European Medicines Agency
- Amgevita: European public assessment report (EPAR) · European Medicines Agency
Need Yusimry 40 mg/0.8 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.